Treatment of hepatitis C virus infection with direct-acting antiviral agent-based regimens in Iranian patients with hereditary bleeding disorders

Table 3 Characteristics of patients who did not achieve rapid virologic response

No	Age	Sex	HBD	Regimen	Liver disease	HCV genotype	Previous treatment experience	Baseline HCV RNA (log₁₀ IU/mL)	Week 4 HCV RNA (log₁₀ IU/mL)	SVR12 status
2	41	Male	HA	SOF/LDV + RBV 24 W	Non-cirrhotic	4	Naïve	6.94	2.24	SVR
5	31	Male	HB	SOF/LDV + RBV 24 W	Non-cirrhotic	1	IFN-based	5.77	3.68	SVR
36	49	Male	HA	SOF/LDV + RBV 12 W	Non-cirrhotic	1	Naïve	5.91	2.53	SVR
59	39	Male	HB	SOF/LDV + RBV 24 W	Compensated cirrhosis	1	IFN-based	6.64	2.62	SVR
122	34	Female	VWD	SOF/LDV + RBV 12 W	Non-cirrhotic	1	Naïve	6.21	2.12	SVR
130	32	Male	HA	SOF/LDV 12 W	Non-cirrhotic	1	IFN-based	7.04	5.59	SVR

HBD hereditary bleeding disorder, HA hemophilia A, HB hemophilia B, VWD Von Willebrand disease, SOF sofosbuvir, LDV ledipasvir, RBV ribavirin, IFN interferon, SVR sustained virologic response, W weeks

ISSN: 1743-422X